RecruitingNCT04753996
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
Sponsor
Mayo Clinic
Enrollment
300 participants
Start Date
Mar 8, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Plain Language Summary
Simplified for easier understanding
This study is collecting bile samples from patients with primary sclerosing cholangitis (PSC) — a chronic liver disease that damages bile ducts — and from people without PSC, to grow specialized tissue cultures called organoids that may help researchers study the disease in the lab.
**You may be eligible if...**
- You are between 18 and 85 years old
- You have been diagnosed with PSC, OR you are a patient without PSC undergoing a bile duct procedure (as a comparison group)
- If you have PSC, you meet standard diagnostic criteria including imaging and lab findings
**You may NOT be eligible if...**
- You are outside the age range
- You do not consent to participate
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04753996
Related Trials
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
NCT046451601 location
FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis
NCT062867095 locations
In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers
NCT072063551 location
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
NCT070301401 location
FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers
NCT074785231 location